An innovative dual action (antimicrobial & immunomodulator) product for the aquaculture feed additives market

Informations projet

AQUAGARLIC

N° de convention de subvention: 887860

DOI

10.3030/887860

Projet clôturé

Date de signature de la CE 31 Octobre 2019

Date de début 1 Novembre 2019

Date de fin 29 Février 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

DOMCA SA
Spain

Periodic Reporting for period 1 - AQUAGARLIC (An innovative dual action (antimicrobial & immunomodulator) product for the aquaculture feed additives market)

Période du rapport: 2019-11-01 au 2020-02-29

Résumé du contexte et des objectifs généraux du projet

Aquacultured fish diseases are a clear indicator of the presence of pathogens (normally microbes and/or parasites). These pathogens can cause health problems to humans when eating the infected fish. Beside this, loss of yield in aquaculture production can rise up to 50% due to this situation. At Domca, we aim to meet the needs of our customers, expanding our sales portfolio while we enter a market of € 1.05 billion (CAGR of 3.2%), offering a new and natural-based revolutionary solution for the protection against parasites and microbes: AQUAgarlic. The objective of this project, AQUAgarlic, is to finish the development phase for the launching of Domca’s new product in the aquaculture market, with the first dual action (antimicrobial and immunomodulator) feed additive for aquaculture industry based on organosulfur natural active ingredients, with zero residues, effective and environmentally friendly. This product would be a game changer, as most related products (synthetic medicines) are not environmentally friendly and are targeted to only one specific threat (microbe or parasite).

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

With this feasibility study we have been able to verify the technical and economic viability of the AQUAgarlic project and we have decided to continue with our business idea. The next step will be to prepare a Phase 2 proposal in order to get the necessary funding for the industrial scale-up of our innovation. We have identified the necessary activities for the next phase 2 project as well as the required resources, and we have confirmed that these are feasible in a reasonable time frame of two years, allowing us to start commercializing our product by Q4 2021 / Q1 2022, according to the business plan defined in this document.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Domca will introduce a turnkey solution in the market that offers clear commercial and technical advantages when compared to the technology currently used in the different industrial sectors where it can be applied:
• Natural food additive for aquaculture, the key active ingredients for this product are extracts from Alliaceae (revaluation of raw agricultural by-products).
• Dose dependent dual action: broad spectrum antimicrobial action, since they attack a large number of pathogenic bacteria that cause infections (gram-positive as gram-negative) and destroy and inhibit parasitic growth.
• Regulate immune system, by increasing or decreasing the ability to produce antibodies.
• Zero residues, eliminating the environmental, animals and human health impact.
• No fish withdrawal time.
• It is a stable product with high thermal and pressure resistance.

AQUAGARLIC LOGO